Gensight Biologics S.a annual free cash flow
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Free Cash Flow (FCF) History (SIGHT)
Gensight Biologics S.a reported −€9.2M in free cash flow for fiscal 2025, an increase of €3.8M from the previous fiscal year, with a free cash flow margin of −917400.00%.
View full Gensight Biologics S.a company overviewGensight Biologics S.a free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −€9.2M | €3.8M | — | −917400.00% |
| 2024 | 2024-12-31 | −€12.9M | €11.7M | — | −862.53% |
| 2023 | 2023-12-31 | −€24.7M | €9.3M | — | −1947.36% |
| 2022 | 2022-12-31 | −€34.0M | −€16.8M | — | −1317.00% |
| 2021 | 2021-12-31 | −€17.2M | −€2.1M | — | −325.45% |
| 2020 | 2020-12-31 | −€15.1M | — | — | −342.51% |
Gensight Biologics S.a free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −€15.1M to −€9.2M, a net increase of €5.9M.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...